AIDS, Not PDUFA Pressure, Underlies Post-Market Safety Event Surge – Lutter
DURHAM, N.C. - Any surge in FDA post-market safety actions stems from the rapid approval of AIDS drugs during the 1990s, and not errors made as a result of review time constraints created by user fee deadlines, Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter maintained June 23
You may also be interested in...
FDA is preparing to rebut an analysis published in the New England Journal of Medicine March 27 suggesting that new molecular entities approved close to review deadlines under the Prescription Drug User Fee Act are more likely to suffer post-market safety problems
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials